Goldman Sachs Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $536 to $320.
Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $536 to $320.